Makale detayı · 2015
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial
Dergi
The Lancet Infectious Diseases
OpenAlex
Açık erişim · bronze
SJR Q1
JCR Q1
Atıf 266
Üst %1
Yüzdelik 99.3%
FWCI 13.82
- Yıl
- 2015
- Tür
- article
Veri kaynağı ayrımı
- YÖKSİS dergi adı The Lancet Infectious Diseases
- OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)
Özet
Özet henüz derlenmedi; DergiPark / OpenAlex kuyruğu işlenince burada görünecek.
Konular
Atıflar
OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.
266 atıf
OpenAlex cited_by_count (önbellek / veritabanı)
Yerel katalogda bu makaleye atıf yapan 18 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).
- Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study 2018
- Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study 2018
- Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study 2018
- Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The lowr HDV - 1 study 2017
- Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The lowr HDV - 1 study 2017
- Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease 2018
- Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease 2018
- A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. 2022
- A Phase ii dose finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis 2021
- Characteristics of Newly Diagnosed Hepatocellular Carcinoma Patients Across Turkey: Prospective Multicenter Observational 3K Registry Study. 2021